Study of MK-8294 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called MK-8294 for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have certain types of cancer and are looking for a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has not responded to or you cannot tolerate standard treatments, including head and neck, cervical, esophageal, breast (triple-negative or hormone-positive/HER2-negative), endometrial, or bladder cancer.
- If you have HIV, it must be well-controlled with antiretroviral therapy.
- If you have hepatitis B, you must be on antiviral therapy for at least 4 weeks and have an undetectable viral load.
- If you have had hepatitis C, your viral load must be undetectable.
- You cannot have had severe side effects from previous immunotherapy that led to stopping treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
This trial tests a new drug, MK-6204, in people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Metastatic Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.